Log in

OTCMKTS:HGENHumanigen Stock Price, Forecast & News

$4.40
+0.44 (+11.11 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.23
Now: $4.40
$4.93
50-Day Range
$0.83
MA: $2.80
$5.02
52-Week Range
$0.30
Now: $4.40
$6.30
Volume290,600 shs
Average Volume196,009 shs
Market Capitalization$923.45 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.54
Humanigen, Inc., a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab targets Ephrin type-A receptor 3 (EphA3), and is being explored as a potential treatment for glioblastoma multiforme (GBM) and other cancers, as well as for use in novel CAR-T construct and bispecific antibody platform. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HGEN
Previous SymbolNASDAQ:KBIO
CUSIPN/A
Phone650-243-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.13) per share

Profitability

Net Income$-10,290,000.00

Miscellaneous

Employees3
Market Cap$923.45 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive HGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for HGEN and its competitors with MarketBeat's FREE daily newsletter.

Humanigen (OTCMKTS:HGEN) Frequently Asked Questions

How has Humanigen's stock been impacted by COVID-19 (Coronavirus)?

Humanigen's stock was trading at $0.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HGEN stock has increased by 576.9% and is now trading at $4.40. View which stocks have been most impacted by Coronavirus.

When is Humanigen's next earnings date?

Humanigen is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Humanigen.

How were Humanigen's earnings last quarter?

Humanigen Inc (OTCMKTS:HGEN) posted its quarterly earnings results on Friday, May, 15th. The company reported ($0.02) EPS for the quarter. View Humanigen's earnings history.

Has Humanigen been receiving favorable news coverage?

Press coverage about HGEN stock has trended negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Humanigen earned a news impact score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Humanigen.

Who are some of Humanigen's key competitors?

What other stocks do shareholders of Humanigen own?

Who are Humanigen's key executives?

Humanigen's management team includes the following people:
  • Dr. Cameron Durrant M.B.A., M.D., MBA, Chairman & CEO (Age 59)
  • Mr. J. Gregory Jester, Chief Financial Officer (Age 51)
  • Mr. Christopher Bowe, Head of Corp. Affairs
  • Dr. Tarek Sahmoud, Chief Medical Officer

What is Humanigen's stock symbol?

Humanigen trades on the OTCMKTS under the ticker symbol "HGEN."

How do I buy shares of Humanigen?

Shares of HGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Humanigen's stock price today?

One share of HGEN stock can currently be purchased for approximately $4.40.

How big of a company is Humanigen?

Humanigen has a market capitalization of $923.45 million. Humanigen employs 3 workers across the globe.

What is Humanigen's official website?

The official website for Humanigen is www.humanigen.com.

How can I contact Humanigen?

Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The company can be reached via phone at 650-243-3100 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.